Latest news with #BioNTechSE
Globe and Mail
3 days ago
- Business
- Globe and Mail
Refractory Metastatic Melanoma Pipeline Appears Robust With 4+ Key Pharma Companies Actively Working in the Therapeutics Segment
DelveInsight's, ' Refractory Metastatic Melanoma Pipeline Insight, 2025 ' report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Refractory Metastatic Melanoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore our latest breakthroughs in Refractory Metastatic Melanoma Research. Learn more about our innovative pipeline today! @ Refractory Metastatic Melanoma Pipeline Outlook Key Takeaways from the Refractory Metastatic Melanoma Pipeline Report In July 2025, Genmab announced clinical trial is to learn about the effectiveness and safety of the bispecific antibody acasunlimab (also known as DuoBody®-PD-L1x4-1BB) when given either alone or together with the cancer drug pembrolizumab in participants with locally advanced or metastatic melanoma of the skin. All participants will receive active drugs; no one will be given a placebo. DelveInsight's Refractory Metastatic Melanoma pipeline report depicts a robust space with 4+ active players working to develop 4+ pipeline therapies for Refractory Metastatic Melanoma treatment. The leading Refractory Metastatic Melanoma Companies such as BioNTech SE, Y-mAbs Therapeutics, Seagen Inc. and others. Promising Refractory Metastatic Melanoma Pipeline Therapies such as GIM-531, Acasunlimab, Pembrolizumab, GSK2118436, GSK1120212, BNT111, Cemiplimab, BA3071, Nivolumab and others. Stay informed about the cutting-edge advancements in Refractory Metastatic Melanoma treatments. Download for updates and be a part of the revolution in Dermatology care @ Refractory Metastatic Melanoma Clinical Trials Assessment Refractory Metastatic Melanoma Emerging Drugs Profile BNT111: BioNTech SE BNT111 is an mRNA cancer vaccine candidate encoding a fixed set of four melanoma-associated antigens aiming to trigger a strong and precise immune response in patients with anti-PD-(L) 1 refractory/relapsed, unresectable Stage III or IV melanoma. BNT111 is an mRNA-based off-the-shelf cancer immunotherapy candidate for intravenous administration encoding a fixed set of four non-mutated melanoma-associated antigens (NY-ESO-1, MAGE-A3, tyrosinase, and TPTE) delivered as uridine mRNA-lipoplex formulation. Over 90% of patients with cutaneous melanomas express at least one of these antigens. The BNT111 program has also received Fast Track designation and Orphan Drug designation from the U.S. Food and Drug Administration. Currently, the drug is in Phase II stage of its development for the treatment of Refractory Metastatic Melanoma. GD2-SADA: Y-mAbs Therapeutics The GD2-SADA construct is created using SADA technology, that utilizes a pre-targeted payload delivery method where antibody constructs assemble in tetramers and bind to the tumor target. Unbound constructs predictably disassemble into smaller antibody fragments and are excreted through the kidneys within hours after administration. In a second infusion, a radioactive payload binds to the antibody constructs attached to the tumor target in order to radiate the tumor. This provides the possibility of targeting tumors with precision while minimizing radiation of normal tissues. The SADA technology platform can deliver a variety of payloads and could potentially be developed against multiple tumor targets, as well as for theragnostic purposes. Currently, the drug is in Phase I stage of its development for the treatment of Refractory Metastatic Melanoma. The Refractory Metastatic Melanoma Pipeline Report provides insights into The report provides detailed insights about companies that are developing therapies for the treatment of Refractory Metastatic Melanoma with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Refractory Metastatic Melanoma Treatment. Refractory Metastatic Melanoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Refractory Metastatic Melanoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Refractory Metastatic Melanoma market. Learn more about Refractory Metastatic Melanoma Drugs opportunities in our groundbreaking Refractory Metastatic Melanoma research and development projects @ Refractory Metastatic Melanoma Unmet Needs Refractory Metastatic Melanoma Companies BioNTech SE, Y-mAbs Therapeutics, Seagen Inc. and others. Refractory Metastatic Melanoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Oral Intravenous Subcutaneous Parenteral Topical Refractory Metastatic Melanoma Products have been categorized under various Molecule types such as Recombinant fusion proteins Small molecule Monoclonal antibody Peptide Polymer Gene therapy Discover the latest advancements in Refractory Metastatic Melanoma treatment by visiting our website. Stay informed about how we're transforming the future of dermatology @ Refractory Metastatic Melanoma Market Drivers and Barriers, and Future Perspectives Scope of the Refractory Metastatic Melanoma Pipeline Report Coverage- Global Refractory Metastatic Melanoma Companies- BioNTech SE, Y-mAbs Therapeutics, Seagen Inc. and others. Refractory Metastatic Melanoma Pipeline Therapies- GIM-531, Acasunlimab, Pembrolizumab, GSK2118436, GSK1120212, BNT111, Cemiplimab, BA3071, Nivolumab and others. Refractory Metastatic Melanoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Refractory Metastatic Melanoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III For a detailed overview of our latest research findings and future plans, read the full details of Refractory Metastatic Melanoma Pipeline on our website @ Refractory Metastatic Melanoma Emerging Drugs and Companies Table of Contents Introduction Executive Summary Refractory Metastatic Melanoma: Overview Pipeline Therapeutics Therapeutic Assessment Refractory Metastatic Melanoma – DelveInsight's Analytical Perspective In-depth Commercial Assessment Refractory Metastatic Melanoma Collaboration Deals Late Stage Products (Phase III) Drug Name: Company Name Drug profiles in the detailed report….. Mid Stage Products (Phase II) BNT111: BioNTech SE Drug profiles in the detailed report….. Early Stage Products (Phase I) GD2-SADA: Y-mAbs Therapeutics Drug profiles in the detailed report… Pre-clinical and Discovery Stage Products Drug name: Company name Drug profiles in the detailed report….. Inactive Products Refractory Metastatic Melanoma Key Companies Refractory Metastatic Melanoma Key Products Refractory Metastatic Melanoma- Unmet Needs Refractory Metastatic Melanoma- Market Drivers and Barriers Refractory Metastatic Melanoma- Future Perspectives and Conclusion Refractory Metastatic Melanoma Analyst Views Refractory Metastatic Melanoma Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
Yahoo
3 days ago
- Business
- Yahoo
Recent Agreements Set To Bolster BioNTech SE (BNTX)'s Oncology Arm
BioNTech SE (NASDAQ:BNTX) is one of the 13 Best German Stocks to Invest in Now. It is a clinical-stage biotechnology company focused on immunotherapies to treat cancer and other serious diseases. A microbiologist observing a petri dish of bacteria under a microscope. On June 2, the company announced that it had agreed with Bristol Myers Squibb for the global joint development and commercialization of BioNTech SE (NASDAQ:BNTX)'s investigational bispecific antibody BNT327 for solid tumor types. Under the terms of the agreement, Bristol Myers Squibb will pay BioNTech SE (NASDAQ:BNTX) up to $11.1 billion for the partnership, including $3.5 billion in unconditional payments. The deal reflects the German company's ambition to continue a costly, long-term focus on cancer treatments, and shows that its collaboration with Pfizer for the COVID-19 vaccine was not a singular achievement. Later in the month, on June 12, BioNTech SE (NASDAQ:BNTX) announced that it would acquire CureVac for approximately $1.25 billion in shares, which is expected to further strengthen the company's research, development, and commercialization of mRNA-based cancer treatments. While we acknowledge the potential of BNTX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: Goldman Sachs Stock Portfolio: 10 Large-Cap Stocks To Buy and 13 Best Big Name Stocks to Buy Now. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Bloomberg
12-06-2025
- Business
- Bloomberg
BioNTech to Buy CureVac for $1.25 Billion to Boost Cancer Arm
BioNTech SE agreed to buy former Covid vaccine rival CureVac NV for about $1.25 billion in an all-stock transaction that will boost its growing oncology business. CureVac investors will get approximately $5.46 in BioNTech shares for each CureVac one, the companies said Thursday. The price represents a 34% premium to CureVac's closing share price on Wednesday. CureVac shareholders will own between 4% and 6% of BioNTech once the deal closes.
Yahoo
03-06-2025
- Business
- Yahoo
Why BioNTech SE (BNTX) Skyrocketed On Monday
We recently published a list of . In this article, we are going to take a look at where BioNTech SE (NASDAQ:BNTX) stands against other top-performing stocks on Monday. BioNTech saw its share prices grow by 18.05 percent on Monday to finish at $113.10 apiece following news that it joined forces with Bristol Myers Squibb for the development of a next-generation cancer immunotherapy for $11.1 billion. In a statement, BioNTech SE (NASDAQ:BNTX) said it partnered with Bristol Myers to broaden and accelerate the development of BNT327 across numerous solid tumor types. A microbiologist observing a petri dish of bacteria under a microscope. Bristol Myers will pay BioNTech SE (NASDAQ:BNTX) $1.5 billion in an upfront payment and $2 billion total in non-contingent anniversary payments through 2028. Additionally, BioNTech SE (NASDAQ:BNTX) will be eligible to receive up to $7.6 billion in additional development, regulatory, and commercial milestones. The two companies will share joint development and manufacturing costs on a 50:50 basis, subject to certain exceptions, and equally share global profits or losses. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
03-06-2025
- Business
- Yahoo
Why BioNTech SE (BNTX) Skyrocketed On Monday
We recently published a list of . In this article, we are going to take a look at where BioNTech SE (NASDAQ:BNTX) stands against other top-performing stocks on Monday. BioNTech saw its share prices grow by 18.05 percent on Monday to finish at $113.10 apiece following news that it joined forces with Bristol Myers Squibb for the development of a next-generation cancer immunotherapy for $11.1 billion. In a statement, BioNTech SE (NASDAQ:BNTX) said it partnered with Bristol Myers to broaden and accelerate the development of BNT327 across numerous solid tumor types. A microbiologist observing a petri dish of bacteria under a microscope. Bristol Myers will pay BioNTech SE (NASDAQ:BNTX) $1.5 billion in an upfront payment and $2 billion total in non-contingent anniversary payments through 2028. Additionally, BioNTech SE (NASDAQ:BNTX) will be eligible to receive up to $7.6 billion in additional development, regulatory, and commercial milestones. The two companies will share joint development and manufacturing costs on a 50:50 basis, subject to certain exceptions, and equally share global profits or losses. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
